Pharmacokinetics of amikacin in cystic fibrosis: A study of bronchial diffusion View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1986-01

AUTHORS

E. Autret, S. Marchand, M. Breteau, B. Grenier

ABSTRACT

Summary36 pharmacokinetic studies of amikacin were performed to evaluate the bronchial diffusion of amikacin in 9 children with cystic fibrosis, 3 to 15 years old. Amikacin was administered i.v. according to a variable dosage regimen. Four children without cystic fibrosis were enrolled as controls. The mean half life was 1.1, the volume of distribution averaged 0.26 l/kg, and the mean plasma clearance was 131 ml/min/1.73 m2, which no differed from that of the controls. The mean peak plasma concentration was always above the MIC but its level depended on the unit dose: 18.5 mg/l, 25,95 mg/l and 31,46 mg/l for doses of 5, 7.5 and 12.5 mg/kg, respectively. Between consecutive amikacin infusions, the plasma level was above the MIC for 21% and 46% of the time after the 5 and 7.5 mg/kg doses. The maximum concentration in sputum between H1 and H2 was always below the MIC, except after 15 mg/kg. The ratio AUC sputum/AUC plasma was between 0.028 and 0.61, and it increased from the beginning to the end of the course of treatment. No side effects were observed on hearing, or vestibular and renal function. The results are used to suggest more appropriate dosing regimens. More... »

PAGES

79-83

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00870991

DOI

http://dx.doi.org/10.1007/bf00870991

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1049329653

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/3780832


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amikacin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bronchi", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cystic Fibrosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diffusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Half-Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kinetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Respiratory Tract Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sputum", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service de Pharmacologie Clinique, C.H.U., Tours, France", 
          "id": "http://www.grid.ac/institutes/grid.411167.4", 
          "name": [
            "Service de Pharmacologie Clinique, C.H.U., Tours, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Autret", 
        "givenName": "E.", 
        "id": "sg:person.01233433262.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233433262.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "D\u00e9partment de P\u00e9diatrie, C.H.U., Tours, France", 
          "id": "http://www.grid.ac/institutes/grid.411167.4", 
          "name": [
            "D\u00e9partment de P\u00e9diatrie, C.H.U., Tours, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marchand", 
        "givenName": "S.", 
        "id": "sg:person.0744041632.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744041632.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de Pharmacologie Clinique, C.H.U., Tours, France", 
          "id": "http://www.grid.ac/institutes/grid.411167.4", 
          "name": [
            "Service de Pharmacologie Clinique, C.H.U., Tours, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Breteau", 
        "givenName": "M.", 
        "id": "sg:person.01265345432.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265345432.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "D\u00e9partment de P\u00e9diatrie, C.H.U., Tours, France", 
          "id": "http://www.grid.ac/institutes/grid.411167.4", 
          "name": [
            "D\u00e9partment de P\u00e9diatrie, C.H.U., Tours, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grenier", 
        "givenName": "B.", 
        "id": "sg:person.0106765542.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0106765542.64"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1986-01", 
    "datePublishedReg": "1986-01-01", 
    "description": "Summary36 pharmacokinetic studies of amikacin were performed to evaluate the bronchial diffusion of amikacin in 9 children with cystic fibrosis, 3 to 15 years old. Amikacin was administered i.v. according to a variable dosage regimen. Four children without cystic fibrosis were enrolled as controls. The mean half life was 1.1, the volume of distribution averaged 0.26 l/kg, and the mean plasma clearance was 131 ml/min/1.73 m2, which no differed from that of the controls. The mean peak plasma concentration was always above the MIC but its level depended on the unit dose: 18.5 mg/l, 25,95 mg/l and 31,46 mg/l for doses of 5, 7.5 and 12.5 mg/kg, respectively. Between consecutive amikacin infusions, the plasma level was above the MIC for 21% and 46% of the time after the 5 and 7.5 mg/kg doses. The maximum concentration in sputum between H1 and H2 was always below the MIC, except after 15 mg/kg. The ratio AUC sputum/AUC plasma was between 0.028 and 0.61, and it increased from the beginning to the end of the course of treatment. No side effects were observed on hearing, or vestibular and renal function. The results are used to suggest more appropriate dosing regimens.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf00870991", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "keywords": [
      "cystic fibrosis", 
      "mean peak plasma concentration", 
      "pharmacokinetics of amikacin", 
      "mean plasma clearance", 
      "appropriate dosing regimens", 
      "peak plasma concentration", 
      "course of treatment", 
      "volume of distribution", 
      "mean half life", 
      "amikacin infusion", 
      "renal function", 
      "dosing regimens", 
      "dosage regimen", 
      "plasma levels", 
      "plasma clearance", 
      "plasma concentrations", 
      "side effects", 
      "amikacin", 
      "fibrosis", 
      "unit dose", 
      "pharmacokinetic study", 
      "MIC", 
      "doses", 
      "half life", 
      "children", 
      "regimen", 
      "regimens", 
      "sputum", 
      "infusion", 
      "maximum concentration", 
      "pharmacokinetics", 
      "dose", 
      "clearance", 
      "levels", 
      "treatment", 
      "control", 
      "study", 
      "hearing", 
      "years", 
      "concentration", 
      "differed", 
      "course", 
      "plasma", 
      "life", 
      "m2", 
      "volume", 
      "effect", 
      "function", 
      "H1", 
      "end", 
      "time", 
      "results", 
      "beginning", 
      "distribution", 
      "diffusion", 
      "H2", 
      "bronchial diffusion", 
      "variable dosage regimen", 
      "consecutive amikacin infusions", 
      "ratio AUC sputum/AUC plasma", 
      "AUC sputum/AUC plasma", 
      "sputum/AUC plasma", 
      "AUC plasma"
    ], 
    "name": "Pharmacokinetics of amikacin in cystic fibrosis: A study of bronchial diffusion", 
    "pagination": "79-83", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1049329653"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00870991"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "3780832"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00870991", 
      "https://app.dimensions.ai/details/publication/pub.1049329653"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T17:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_192.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf00870991"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00870991'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00870991'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00870991'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00870991'


 

This table displays all metadata directly associated to this object as RDF triples.

204 TRIPLES      21 PREDICATES      104 URIs      96 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00870991 schema:about N02e8cbbdd0114aa18b13ec464356eb91
2 N0b5ecd9899d84c5a9a4457e5cb7f1631
3 N16d45a098b324e648baaf393f381b51a
4 N3f3c761205034009ae6d747b0450d54e
5 N5c0115d6122345e8a4a38211ec539264
6 N67ebadcf494543739ede729a00a1d277
7 N6c0437f3d74444599ab5dd949e92bcf1
8 N74b8cc41a8354600b2bf1053403f57e8
9 N8c0e52f8479d48b6ba7826e9f37b31e6
10 N9291e83f382b48d7a98e84590e6065a4
11 Nce5fe26830724c4fa1011d0d9a3724ef
12 Ncf95ba2e121e4675a672f0a553d6c12c
13 Nf6fcc288acff465fa7165990c77e5d36
14 Nfb3f4652822d422fb7500d1c3c29e478
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N6027997dd902457198a017e8411e8fb9
18 schema:datePublished 1986-01
19 schema:datePublishedReg 1986-01-01
20 schema:description Summary36 pharmacokinetic studies of amikacin were performed to evaluate the bronchial diffusion of amikacin in 9 children with cystic fibrosis, 3 to 15 years old. Amikacin was administered i.v. according to a variable dosage regimen. Four children without cystic fibrosis were enrolled as controls. The mean half life was 1.1, the volume of distribution averaged 0.26 l/kg, and the mean plasma clearance was 131 ml/min/1.73 m2, which no differed from that of the controls. The mean peak plasma concentration was always above the MIC but its level depended on the unit dose: 18.5 mg/l, 25,95 mg/l and 31,46 mg/l for doses of 5, 7.5 and 12.5 mg/kg, respectively. Between consecutive amikacin infusions, the plasma level was above the MIC for 21% and 46% of the time after the 5 and 7.5 mg/kg doses. The maximum concentration in sputum between H1 and H2 was always below the MIC, except after 15 mg/kg. The ratio AUC sputum/AUC plasma was between 0.028 and 0.61, and it increased from the beginning to the end of the course of treatment. No side effects were observed on hearing, or vestibular and renal function. The results are used to suggest more appropriate dosing regimens.
21 schema:genre article
22 schema:inLanguage en
23 schema:isAccessibleForFree false
24 schema:isPartOf N21c76d57df394b5eab7364ad122ee352
25 N3781e9942d684bc6838a7bc75aea01de
26 sg:journal.1054337
27 schema:keywords AUC plasma
28 AUC sputum/AUC plasma
29 H1
30 H2
31 MIC
32 amikacin
33 amikacin infusion
34 appropriate dosing regimens
35 beginning
36 bronchial diffusion
37 children
38 clearance
39 concentration
40 consecutive amikacin infusions
41 control
42 course
43 course of treatment
44 cystic fibrosis
45 differed
46 diffusion
47 distribution
48 dosage regimen
49 dose
50 doses
51 dosing regimens
52 effect
53 end
54 fibrosis
55 function
56 half life
57 hearing
58 infusion
59 levels
60 life
61 m2
62 maximum concentration
63 mean half life
64 mean peak plasma concentration
65 mean plasma clearance
66 peak plasma concentration
67 pharmacokinetic study
68 pharmacokinetics
69 pharmacokinetics of amikacin
70 plasma
71 plasma clearance
72 plasma concentrations
73 plasma levels
74 ratio AUC sputum/AUC plasma
75 regimen
76 regimens
77 renal function
78 results
79 side effects
80 sputum
81 sputum/AUC plasma
82 study
83 time
84 treatment
85 unit dose
86 variable dosage regimen
87 volume
88 volume of distribution
89 years
90 schema:name Pharmacokinetics of amikacin in cystic fibrosis: A study of bronchial diffusion
91 schema:pagination 79-83
92 schema:productId N2bf52e314a794bb7a2698d3f25ec5147
93 N71940658b9b7441ba7750018217defda
94 Nc2d9c3c575a44955a3f434ad328f5c9f
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049329653
96 https://doi.org/10.1007/bf00870991
97 schema:sdDatePublished 2021-11-01T17:57
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher N9720921a2ad144958fc91cc8c2c30628
100 schema:url https://doi.org/10.1007/bf00870991
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N02e8cbbdd0114aa18b13ec464356eb91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Cystic Fibrosis
106 rdf:type schema:DefinedTerm
107 N0b5ecd9899d84c5a9a4457e5cb7f1631 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Bronchi
109 rdf:type schema:DefinedTerm
110 N11cac7412d1a4fdcad103411bd675118 rdf:first sg:person.0744041632.29
111 rdf:rest Nc614fac60a0e48669ed74a0adfdca1e4
112 N15242a81cdd74960befb5af2fe33b941 rdf:first sg:person.0106765542.64
113 rdf:rest rdf:nil
114 N16d45a098b324e648baaf393f381b51a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Adolescent
116 rdf:type schema:DefinedTerm
117 N21c76d57df394b5eab7364ad122ee352 schema:volumeNumber 31
118 rdf:type schema:PublicationVolume
119 N2bf52e314a794bb7a2698d3f25ec5147 schema:name pubmed_id
120 schema:value 3780832
121 rdf:type schema:PropertyValue
122 N3781e9942d684bc6838a7bc75aea01de schema:issueNumber 1
123 rdf:type schema:PublicationIssue
124 N3f3c761205034009ae6d747b0450d54e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Half-Life
126 rdf:type schema:DefinedTerm
127 N5c0115d6122345e8a4a38211ec539264 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Amikacin
129 rdf:type schema:DefinedTerm
130 N6027997dd902457198a017e8411e8fb9 rdf:first sg:person.01233433262.98
131 rdf:rest N11cac7412d1a4fdcad103411bd675118
132 N67ebadcf494543739ede729a00a1d277 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Sputum
134 rdf:type schema:DefinedTerm
135 N6c0437f3d74444599ab5dd949e92bcf1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Diffusion
137 rdf:type schema:DefinedTerm
138 N71940658b9b7441ba7750018217defda schema:name doi
139 schema:value 10.1007/bf00870991
140 rdf:type schema:PropertyValue
141 N74b8cc41a8354600b2bf1053403f57e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Male
143 rdf:type schema:DefinedTerm
144 N8c0e52f8479d48b6ba7826e9f37b31e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Kinetics
146 rdf:type schema:DefinedTerm
147 N9291e83f382b48d7a98e84590e6065a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Child, Preschool
149 rdf:type schema:DefinedTerm
150 N9720921a2ad144958fc91cc8c2c30628 schema:name Springer Nature - SN SciGraph project
151 rdf:type schema:Organization
152 Nc2d9c3c575a44955a3f434ad328f5c9f schema:name dimensions_id
153 schema:value pub.1049329653
154 rdf:type schema:PropertyValue
155 Nc614fac60a0e48669ed74a0adfdca1e4 rdf:first sg:person.01265345432.75
156 rdf:rest N15242a81cdd74960befb5af2fe33b941
157 Nce5fe26830724c4fa1011d0d9a3724ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Humans
159 rdf:type schema:DefinedTerm
160 Ncf95ba2e121e4675a672f0a553d6c12c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Child
162 rdf:type schema:DefinedTerm
163 Nf6fcc288acff465fa7165990c77e5d36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Female
165 rdf:type schema:DefinedTerm
166 Nfb3f4652822d422fb7500d1c3c29e478 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Respiratory Tract Infections
168 rdf:type schema:DefinedTerm
169 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
170 schema:name Medical and Health Sciences
171 rdf:type schema:DefinedTerm
172 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
173 schema:name Clinical Sciences
174 rdf:type schema:DefinedTerm
175 sg:journal.1054337 schema:issn 0031-6970
176 1432-1041
177 schema:name European Journal of Clinical Pharmacology
178 schema:publisher Springer Nature
179 rdf:type schema:Periodical
180 sg:person.0106765542.64 schema:affiliation grid-institutes:grid.411167.4
181 schema:familyName Grenier
182 schema:givenName B.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0106765542.64
184 rdf:type schema:Person
185 sg:person.01233433262.98 schema:affiliation grid-institutes:grid.411167.4
186 schema:familyName Autret
187 schema:givenName E.
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233433262.98
189 rdf:type schema:Person
190 sg:person.01265345432.75 schema:affiliation grid-institutes:grid.411167.4
191 schema:familyName Breteau
192 schema:givenName M.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265345432.75
194 rdf:type schema:Person
195 sg:person.0744041632.29 schema:affiliation grid-institutes:grid.411167.4
196 schema:familyName Marchand
197 schema:givenName S.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744041632.29
199 rdf:type schema:Person
200 grid-institutes:grid.411167.4 schema:alternateName Départment de Pédiatrie, C.H.U., Tours, France
201 Service de Pharmacologie Clinique, C.H.U., Tours, France
202 schema:name Départment de Pédiatrie, C.H.U., Tours, France
203 Service de Pharmacologie Clinique, C.H.U., Tours, France
204 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...